An ovarian follicle is composed of an oocyte and surrounding theca and granulosa cells. Oocytes are stored in an arrested state within primordial follicles until they are signaled to re-initiate development by undergoing primordial-to-primary follicle transition. Previous gene bionetwork analyses of primordial follicle development identified a number of critical cytokine signaling pathways and genes potentially involved in the process. In the current study, candidate regulatory genes and pathways from the gene network analyses were tested for their effects on the formation of primordial follicles (follicle assembly) and on primordial follicle transition using whole ovary organ culture experiments. Observations indicate that the tyrphostin inhibitor (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one increased follicle assembly significantly, supporting a role for the MAPK signaling pathway in follicle assembly. The cytokine interleukin 16 (IL16) promotes primordial-to-primary follicle transition as compared with the controls, where as Delta-like ligand 4 (DLL4) and WNT-3A treatments have no effect. Immunohistochemical experiments demonstrated the localization of both the cytokine IL16 and its receptor CD4 in the granulosa cells surrounding each oocyte within the ovarian follicle. The tyrphostin LDN193189 (LDN) is an inhibitor of the bone morphogenic protein receptor 1 within the TGFB signaling pathway and was found to promote the primordial-to-primary follicle transition. Observations support the importance of cytokines (i.e., IL16) and cytokine signaling pathways in the regulation of early follicle development. Insights into regulatory factors affecting early primordial follicle development are provided that may associate with ovarian disease and translate to improved therapy in the future.
Introduction
The mammalian ovary is a dynamic organ in which germ cells go through many developmental stages to produce functional gametes. Development through these stages is initiated and regulated by different secreted growth factor and hormonal signals at different developmental points during oocyte maturation. During late fetal development in humans and early postnatal development in rodents, pre-granulosa cells and stromal mesenchymal cells surround the oogonia present in germ cell nests that then undergo follicle assembly to form primordial follicles (Skinner 2005; Fig. 1) . A primordial follicle is composed of a single oocyte surrounded by a single layer of flattened squamous pre-granulosa cells (Skinner 2005) . Primordial follicle assembly creates the pool of primordial follicles available during the reproductive life of the female. If selected for further development, the quiescent primordial follicles undergo the primordial-to-primary follicle transition. This is characterized by an increase in oocyte size and by proliferation of the cuboidal pre-granulosa cells that surround each oocyte (Fortune 2003 , McLaughlin & McIver 2009 , Kenngott et al. 2013 Fig. 1B and C) . Investigation of the cascade of molecular events involved in ovarian follicle development will provide insights into the etiology of certain ovarian diseases such as primary ovarian insufficiency (POI). POI is characterized by early depletion of the pool of arrested primordial follicles, and by induction of menopause before the age of 40 years (Coulam et al. 1986) . POI affects w1% of women in the USA (Dixit et al. 2010) . Understanding the molecular factors in early follicle development could lead to solutions for some infertilities in humans.
Previous studies have lead to the construction of proposed regulatory gene networks for primordial follicle assembly (Nilsson et al. 2013 ) and the primordial-to-primary follicle transition (Nilsson et al. 2010 ). In the current study, several signaling pathways and cytokine growth factors that were identified to potentially regulate primordial follicle development have been chosen to test experimentally. Follicle assembly has previously been shown to be regulated by several cytokines and growth factors that act in part by signaling through the MAPK signaling pathway. These include brain-derived neurotrophic factor (Kerr et al. 2009 ), tumor necrosis factor a (Morrison & Marcinkiewicz 2002 , Nilsson et al. 2006a , and kit ligand (KITLG) (Wang & Roy 2004) . The MAPK and focal adhesion pathways have also been reported to be involved in gene networks previously proposed to regulate follicle assembly (Nilsson et al. 2013) . Certain tyrphostin inhibitors (Levitzki 1996) are utilized in the current study to test whether the MAPK and focal adhesion pathways are involved in early ovarian follicle development. Tyrphostin inhibitor SP600125 inhibits c-Jun N-terminal kinase (JNK) in both the focal adhesion pathway and the MAPK signaling pathway. One would predict that this would lead to inhibited ovarian follicle assembly. (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) is an allosteric inhibitor of MAPK phosphatases (MKPs), specifically dual-specificity phosphatase 6 (DUSP6), in the MAPK signaling pathway. DUSP6 is itself an inhibitor of ERK1/2 and JNK. BCI treatment can then be expected to stimulate ovarian follicle assembly.
The mRNA expression levels of interleukin 16 (IL16), Wingless-type MMTV integration site family, member 2B (WNT2B), and Delta-like ligand 4 (DLL4) have been found to change during primordial-to-primary follicle transition (Nilsson et al. 2010) . IL16 is a cytokine known to act as a chemoattractant for CD4CT-cells in immune responses throughout the body (Kanehisa & Goto 2000 , Mathy et al. 2000 , Cruikshank & Little 2008 . ILs have also been found in various ovarian cells including oocytes and supporting follicle cells in mammals, and have been shown to be secreted from macrophages in the ovary (Smolikova et al. 2012) . Wnt2b is known to bind to the members of the Frizzled receptor family, which are a part of the Wnt signaling pathway. Wnt3a is also known to act on this same set of receptors (Kanehisa & Goto 2000 , Lapointe & Boerboom 2011 , Sirotkin 2011 . The members of the Wnt signaling pathway have been found to be expressed in the ovary and to regulate follicle development and steroidogenesis (Richards & Pangas 2010 , Lapointe & Boerboom 2011 , Sirotkin 2011 . Dll4 is known to bind to Notch receptors to activate the Notch signaling pathway (Kanehisa & Goto 2000 , Andrawes et al. 2013 . Notch has been shown to influence multiple cellular processes including: cell fate decisions, proliferation, apoptosis, migration, and plasticity, and seems to be especially essential for angiogenesis (Thomas et al. 2013 ). In the current study, the roles of IL16, Wnt3a (as a functional substitute for Wnt2b which is not commercially available), and Dll4 in primordial-to-primary follicle transition are investigated.
The roles of the MAPK and focal adhesion pathways on the primordial follicle transition are investigated in the current study using the inhibitors SP600125 and BCI. The role of the TGFb signaling pathway is investigated using 4-(6-(4-(1-piperazinyl)phenyl]pyrazolo (1,5-a)pyrimidin-3-yl)-quinoline dihydrochloride (LDN193189). LDN193189 inhibits bone morphogenetic protein receptor 1 (BMPR1) in the TGFB signaling pathway. BMPR1 is a component of the receptor complex that anti-Mü llerian hormone (AMH) and bone morphogenetic proteins (BMP) bind (Nilsson et al. 2011) . AMH is a protein hormone previously shown to have inhibitory action on both primordial follicle assembly (Nilsson et al. 2011 ) and primordial-to-primary follicle transition (Nilsson et al. 2007) . Therefore LDN would be expected to stimulate the primordial follicle transition.
The current study investigates the actions of candidate regulatory factors and selected signaling pathways on ovarian follicle assembly and primordial-to-primary follicle transition. The objective is to test candidate regulatory pathways controlling follicle assembly with ovarian organ culture experiments using the tyrphostin inhibitors SP600125 and BCI. The candidate regulatory factors and pathways potentially controlling the primordial-to-primary follicle transition are tested using the cytokines IL16, Dll4, and Wnt3a, and tyrphostin inhibitors SP600125, BCI, and LDN193189. In addition, the localization of endogenous IL16 and its receptor CD4 in ovarian follicles are determined using immunohistochemistry.
Materials and methods

Organ culture and data collection
Ovaries were removed from 0-day old Sprague-Dawley rat pups (for ovary follicle assembly studies) and 4-day-old rat pups (for ovary follicle transition studies). The animals were obtained from the Washington State University Center for Reproductive Biology Animal Core breeding colonies. All experimental protocols for the procedures with rats were pre-approved by the Washington State University Animal Care and Use Committee (IACUC approval # 02568-026). These ovaries were then placed into a whole organ culture system as described previously (Nilsson et al. 2002 (Nilsson et al. , 2007 (Nilsson et al. , 2011 . The whole organ culture system allows for modeling of multi-tissue biological processes. The culture medium contains 10 mg/ml gentamycin, (Nilsson et al. 2007 (Nilsson et al. , 2011 . Ovaries were cultured for 2 days in the case of follicle assembly studies (Nilsson et al. 2011) , and for 10 days in the case of primordialto-primary follicle transition studies (Nilsson et al. 2002) . At the completion of the culture period, ovaries were processed as described previously (Nilsson et al. 2007 (Nilsson et al. , 2010 (Nilsson et al. , 2011 . After fixation, sectioning at 3 mM thickness, and staining, the ovaries and follicles in each ovarian cross-section were categorized as either oocytes unassembled in nests, primordial follicles (stage 0), early primary i), primary ii), transitional iii), or pre-antral follicles iv) ( Fig. 1B and C) as described previously (Nilsson et al. 2010 (Nilsson et al. , 2011 . The oocytes and follicles from two adjacent sections of the largest cross-section of each ovary were counted and categorized, and then the counts in each category were averaged. In this way, two almost identical ovarian sections are evaluated, and an average number of unassembled oocytes, primordial follicles, and developing follicles are determined across those sections. Only oocytes with visible nuclei are counted. The total number of follicles was determined for each ovary cross section for each treatment, as well as the percent of follicles at each stage of development. These results were analyzed with ANOVA, Student's t-tests, and Dunnet's post hoc tests for specific comparisons.
Immunohistochemistry
Immunohistochemical procedures were carried out for IL16 and its known receptor CD4 in order to localize their expression in the developing ovary. Formalin-fixed tissues from 14-day-old and 19-day-old rat pups were used for immunohistochemical staining as described previously (Nilsson et al. 2002) . The ovary sections were incubated with a blocking buffer (10% goat serum (normal goat serum) or 10% rabbit serum (normal rabbit serum)), followed by the primary antibody, either anti-IL16 (Santa Cruz Biotechnology, Inc., cat# sc-7902) (made in rabbit, 0.2, 0.8, or 4 mg/ml) or anti-CD4 (Santa Cruz Biotechnology, Inc., cat# sc-1140) (made in goat, 0.2, 0.8, or 4 mg/ml) for antigen binding. Secondary antibody was biotinylated anti-rabbit IgG made in goat (Vector Laboratories, Inc., cat# BA-1000, Burlingame, CA, USA) or biotinylated anti-goat IgG made in rabbit (Vector Laboratories, Inc., cat# BA-5000). The ovary sections were incubated with streptavidin-peroxidase Complex (Invitrogen, cat# 50-420Z) for enzyme coupling. A color reaction was performed using a DAB peroxidase substrate kit (Vector Laboratories, Inc., cat# SK-4100). Images were taken of the stained sections and the results were qualitatively analyzed.
Results
Ovarian organ culture experiments were used to investigate the potential role of candidate regulatory factors and selected signaling pathways on ovarian follicle assembly and/or primordial-to-primary follicle transition. For follicle assembly studies we used ovaries removed from 0-day-old rats and cultured for 2 days before being fixed and evaluated (Fig. 1) . These 0-day-old rat ovaries contain predominately nests of oocytes not yet assembled into follicles (Nilsson et al. 2011) . For primordial-to-primary follicle transition studies we used ovaries removed from 4-day-old rats and then cultured them for 10 days with replacement of organ culture medium every other day. These 4-day-old rat ovaries contain predominately assembled primordial follicles (Nilsson et al. 2007 ; Fig. 1 ). After culture and treatment, the ovaries were then fixed, sectioned, and evaluated for their proportions of unassembled oocytes, primordial follicles, and developing follicles as described in Materials and methods. The regulatory factors and pathways were selected for further investigation from previous system biology gene bionetwork studies (Nilsson et al. 2010 (Nilsson et al. , 2013 .
Primordial follicle assembly
In order to test the importance of the MAPK signaling pathway to the follicle assembly process, 0-day-old ovaries were cultured for 2 days with or without the tyrphostin inhibitor compounds BCI and SP600125 (see Materials and methods). BCI acts indirectly to stimulate ERK1/2 and JNK. Both ERK and JNK play prominent roles in the MAPK pathway (Fig. 2) . After 2 days of culture, untreated control ovaries had 26G3.0% assembled follicles. The ovaries treated with BCI (1 mM) had a significant increase in assembled follicles as compared with the control with 40G5.0% assembled into primordial follicles (Fig. 3A) . There was no significant difference in the total oocyte count between control and BCI-treated ovaries, indicating that oocyte death was not a confounding factor in these studies (Fig. 4B ). These results indicate that stimulation of the MAPK pathway promotes the follicle assembly process.
The tyrphostin inhibitor SP600125 inhibits JNK in the MAPK and focal adhesion pathways (Fig. 2) , and therefore decreases the activity of these pathways. Treatment of ovaries from 0-day-old rats with SP600125 did not have a significant effect on follicle assembly, as compared with the untreated controls. A 10 mM SP600125 treatment resulted in 28G3.8%
Cytokines and primordial follicle development assembled follicles, while 50 mM treatment with SP600125 resulted in 26G4.5% assembled follicles (Fig. 3A) . This indicates that inhibition of the focal adhesion and MAPK pathways did not affect the follicle assembly process. This would also indicate that inhibition of JNK in the MAPK pathway has no effect on ovarian follicle assembly. However, treatment with SP600125 at 50 mM concentration did result in a significant decrease in number of follicles per crosssection (31G7.2), as compared with controls (78G12.3) (Fig. 3B) . SP600125 treatment at 50 mM was also observed to result in disorganized follicles with deteriorating cell nuclei (data not shown). This toxicity only occurs at the higher levels of the inhibitor. Together these observations indicate that increased MAPK signaling promoted follicle assembly, but that decreased MAPK and focal adhesion pathway signaling had little effect.
Primordial-to-primary follicle transition
A previous study suggests that the MAPK signaling pathway is a component of the gene network that regulates primordial follicle transition (Nilsson et al. 2010) . In order to test this hypothesis, ovaries from 4-day-old rats were cultured for 10 days in the presence or absence of BCI or SP600125. BCI treatment resulted in no significant change in the proportion of developing follicles (1 mM: 64G4.8%, 5 mM: 51G4.6%) as compared with the untreated controls (58G2.4%) (Fig. 4A ). There were also no significant differences in total follicle count between these treatment groups ( Fig. 4B ), indicating that oocyte death was not a confounding factor in these studies. Similarly, treatment with SP600125 resulted in no significant change in the proportion of developing follicles compared with the untreated controls (Fig. 4C ). There was also no significant difference in total follicle count (Fig. 4D ). These observations indicate that the MAPK and focal adhesion signaling pathways may not play prominent roles in the regulation of primordial-to-primary follicle transition, or that compensatory pathways exist. Therefore, growth factors known to affect follicle transition may act through additional parallel signaling pathways.
Previous research has shown that AMH produced by larger developing follicles will inhibit the primordialto-primary follicle transition (Visser & Themmen 2005 , Nilsson et al. 2007 2001, Nilsson & Skinner 2003) . AMH and BMP growth factors can act through the BMPR1 branch of the TGFB family signaling pathway (Fig. 5 ). In the current study, ovaries were treated with the tyrphostin inhibitor LDN, which inhibits BMPRI, in order to determine how disruption of this TGFB family signaling pathway affects ovarian follicle development (Fig. 5) . The control ovaries for these experiments were treated with dimethylsulfoxide vehicle. Control ovaries were found to have 46G2.2% developing follicles. LDN treatment at a concentration of 0.03 mg/ml resulted in a significant increase (P!0.05) in the proportion of developing follicles, with 60G1.7% of the follicles in the developing stages. Treatment with LDN plus 50 ng/ml AMH also resulted in a significant increase in developing follicles with 56G2.1% development (Fig. 6A ). There were no significant differences between treatment groups in the total number of follicles per ovarian cross-section (Fig. 6B) . The results for this treatment indicate that the BMP/AMH portion of the TGFB signaling pathway plays a role in primordialto-primary follicle transition, and that the inhibitory actions of AMH are blocked by LDN treatment. Previous research had suggested that specific secreted growth factors and cytokines might have a role in the regulation of the primordial-to-primary follicle transition (Nilsson et al. 2010 ; Fig. 7) . Three of these candidate regulatory factors, Wnt3a (as a functional substitute for Wnt2b), Dll4, and IL16 were chosen for evaluation. After the culture period, the untreated control ovaries had an average of 50G2.3% developing follicles. Neither Wnt3a nor DLL4 treatment resulted in any significant difference in the proportion of primordial to developing follicles as compared with the controls (Fig. 8A ). There was also no significant difference in total follicle count between any of these treatment groups and the controls (Fig. 8B) . In these experiments, positive control treatments with KITLG plus FGF2 were carried out, which stimulated primordialto-primary follicle transition, as expected. This indicates that experimental conditions supports follicle transition, even though WNT3A and DLL4 did not stimulate this.
The ovaries treated with 100 ng/ml IL16 had 57G1.4% developing follicles, which was a significant increase (P!0.01) compared with the corresponding control group (50G1.6%). The ovaries treated with 500 ng/ml IL16 had a mean of 58G1.9% developing follicles, which was also a significant increase compared with the control (Fig. 9A) . IL16 treatment at 20 ng/ml had no significant effect. None of the IL16 treatments had a significant effect on the total counts of ovarian follicles as compared with the controls (Fig. 9B) . These data suggest that the cytokine IL16 has a role in the regulation of the primordialto-primary ovarian follicle transition. This supports the importance of IL16 as part of a proposed network of genes regulating the primordial follicle transition (Fig. 7) . As IL16 treatment had a significant effect on the primordialto-primary follicle transition, immunohistochemical experiments were carried out to localize IL16 and its receptor CD4 within the ovary. Both IL16 and CD4 were found to be at highest levels in the granulosa cells of the developing follicle structures, including developing primordial follicles (Fig. 10) . Negative controls using either nonspecific IgG as primary antibody, or using no primary antibody, showed no differential staining of granulosa cells compared with other ovarian cell types (Fig. 10) . The observations suggest that IL16 is an active part of the network of genes regulating the primordial follicle transition, and that an apparent autocrine signaling loop between IL16 and CD4 is maintained in the granulosa cells of developing follicles. 
Cytokines and primordial follicle development
Discussion
Previous studies have used a systems biology approach to identify gene networks that potentially regulate primordial follicle assembly (Nilsson et al. 2013 ) and the primordialto-primary follicle transition (Nilsson et al. 2010) . In these studies, the MAPK and focal adhesion signaling pathways were involved as mediating some of the actions of these proposed regulatory networks for both follicle assembly and the primordial follicle transition. In addition, examination of the proposed regulatory network for primordial follicle transition suggested that the TGFB signaling may be important, as well as WNT, Delta/Notch, and IL cytokine signaling. In the current study, these proposed regulatory gene networks are experimentally evaluated.
Primordial follicle assembly
In order to evaluate the roles of the MAPK and focal adhesion pathways in follicle assembly, 0-day-old rat ovaries were cultured and treated with the tyrphostin inhibitors BCI and SP600125. BCI has been shown to directly and specifically inactivate DUSP6 within the MAPK signaling pathway (Molina et al. 2009) . DUSP6 is itself an inhibitor of ERK1/2 and JNK (Fig. 2) , therefore the end result of BCI treatment is to increase MAPK activity. MAP kinases control many cellular events from embryogenesis, cell differentiation, cell proliferation, and cell death, to short-term changes required for homeostasis and acute hormonal responses (Chen et al. 2001) . ERK1 and ERK2 are two specific MAP kinases that are coexpressed in all mammalian tissues and implicated as key regulators of cell proliferation and differentiation as well as oocyte maturation in culture (Su et al. 2002) . The ovaries treated with BCI showed a significant increase in assembled follicles as compared with the controls. The observations indicate that increasing the activity of the MAPK pathway promotes the follicle assembly process (Fig. 11) . This supports the previously proposed gene network for regulation of follicle assembly (Nilsson et al. 2013) .
In order to test the effect of inhibiting the MAPK pathway during primordial follicle assembly these 0-day-old ovaries were cultured with SP600125. SP600125 is a small molecule inhibitor of JNK (Bennett et al. 2001) , which plays a role in both the focal adhesion and MAPK signaling pathways. Both JNK and c-Jun have been shown to be essential for cell cycle progression and cell proliferation, and previous research has shown that inhibition of JNK via SP600125 halts in vitro growth of mouse preantral follicles (Oktem et al. 2011) . In the present study, SP600125 treatment had no affect on the percentage of assembled ovarian follicles as compared with the controls. These results suggest that inhibition of JNK in either the focal adhesion pathway or the MAPK pathway does not have an effect on follicle assembly. Because of the significant decrease in total follicle number in ovaries treated with high concentrations of SP600125, the results also suggest that the SP600125 inhibitor has a toxic effect at higher concentrations. The ovaries treated with high concentrations of SP600125 have disorganized morphology and signs of necrotic cell death (data not shown).
An explanation is needed as to why BCI had an effect on follicle assembly via the MAPK pathway, whereas SP600125 did not. The inhibition of DUSP6 with BCI amplifies the proliferative effect of c-Jun and JNK signaling (Fig. 2) . SP600125 decreases activity in this pathway by inhibiting JNK. This would mean that a decrease in activity in the MAPK pathway does not have an effect on follicle assembly, but an increase in activity at the JNK site does in fact affect development. This suggests that MAPK activity is sufficient to stimulate increased follicle assembly, but that the activity of the pathway is not necessary for follicle assembly to occur, perhaps because of compensation with other signaling pathways. Further investigation is needed to clarify the molecular mechanisms underlying the differences in response to BCI and SP600125 treatments.
Primordial-to-primary follicle transition
A previous systems biology investigation showed that mRNA expression levels of the secreted growth factors Wnt2b, Dll4, and IL16 changed in ovaries during primordial-to-primary follicle transition ( Fig. 7 ; Nilsson et al. 2010 ). In the current study, organ culture experiments were carried out to directly test whether these signaling molecules regulate follicle transition. Wnt3a acts on the same receptor as Wnt2b and is assumed to have the same physiological effects; therefore Wnt3a was used as a functional substitute treatment factor to determine effects on ovarian follicle primordial to primary transition. The WNT2B is not commercially available. In this study, Wnt3a had no significant effect on the primordialto-primary follicle transition as compared with the controls. Even though Wnt2b is known to be present in the ovary, it has been shown that when the Wnt2b gene was knocked out in mice that were viable, fertile, and had a normal reproductive lifespan (Tsukiyama & Yamaguchi 2012) . This indicates that Wnt2b is not essential for follicle transition despite its presence in the ovary and/or that compensatory factors exist. A previous study suggests that Wnt2b mRNA expression in the ovary is localized to the rat ovarian surface epithelium (Ricken et al. 2002) . This would support the idea that Wnt2b may have an indirect supporting role within the ovary with regard to follicle development.
DLL4 is known to bind to Notch receptors to activate the Notch signaling pathway (Musse et al. 2012) . Notch has been shown to influence multiple cellular processes including: cell fate decisions, proliferation, apoptosis, migration, and plasticity, and seems to be especially essential for processes such as angiogenesis (Thomas et al. 2013) . In a previous study, Dll4 was shown to be expressed in ovaries (Nilsson et al. 2010 ), but in this study DLL4 treatment resulted in no significant changes in the percentage of follicle transition as compared with the controls (Fig. 8) . This may indicate a nonessential supporting role of DLL4 within the ovary. Alternatively, Dll4 expression at the time of follicle transition may prepare the way for vascular development that occurs later as follicle develop. In a previous study, loss of Dll4 expression or Notch signaling has lead to abnormal development of the vascular network, but was not shown to be directly related to the process of angiogenesis (Mettouchi 2012) .
IL16 is a cytokine often associated with immune response, especially for immunoregulatory responses (Mahindra & Anderson 2012) . IL16 is produced by CD8-positive T cells and its known receptor is the CD4 molecule (Cruikshank et al. 1996) . A previous study showed that mRNA expression levels of IL16 changed in ovaries during primordial-to-primary follicle transition (Nilsson et al. 2010 ; Fig. 7 ). Based on these data, organ culture experiments were conducted to test the activity of IL16 within the ovary, and immunohistochemical experiments were then carried out to specifically locate both IL16 and Figure 7 Scheme of direct connections between candidate regulatory growth factors and receptors previously found to be differentially expressed during primordial follicle transition. Circles around genes identify the candidate genes investigated. Nodes represent secreted extracellular signaling molecules and receptors that change in expression level during primordialto-primary follicle transition (except Notch1, which does not change in expression). Node shapes code: diamond -ligand; ice cream conereceptor. Green color represents the regulatory factors investigated in this paper. Connecting arrows represent relationships between genes present in published literature. Arrows with plus sign show positive regulation/activation, arrows with minus sign -negative regulation/inhibition, purple connections represent direct binding. Adapted from Nilsson et al. (2010) .
Cytokines and primordial follicle development its receptor CD4 in developing ovaries. The organ culture experiments demonstrated a moderate increase in primordial-to-primary follicle transition as compared with the controls. The immunohistochemical experiments showed that both IL16 and CD4 proteins were located within the granulosa cells of ovarian follicles, suggesting an autocrine signaling loop. Therefore, IL16 appears to promote the primordial follicle transition process (Fig. 11) .
A systems biology investigation of the primordialto-primary follicle transition predicted that MAPK signaling was involved in this process (Nilsson et al. 2010) . The importance of MAPK signaling in the regulation of the primordial-to-primary follicle transition was investigated in the current studies by using the tyrphostin inhibitors BCI and SP600125 to treat 4-day-old rat ovaries cultured for 10 days. The ovaries treated with BCI at this stage of development showed no significant difference compared with the controls. This suggests that stimulating the MAPK pathway may not be an important mode of regulating the ovarian primordial-to-primary follicle transition, even though it did seem to have an effect earlier in the developmental process. The ovaries treated with SP600125 at this stage also showed no significant difference between untreated controls and the treated ovaries, at either treatment concentration. This indicates that neither directly inhibiting JNK within the MAPK pathway nor inhibiting the focal adhesion pathway affects development at this stage and therefore neither is vital for regulating the primordial follicle transition. Several growth factors that can act in part by signaling through the MAPK pathway have been shown to regulate the primordial-to-primary follicle transition, including PDGF (Nilsson et al. 2006b ), FGF2 (Nilsson et al. 2001 , Jin et al. 2005 , Chaves et al. 2012 , NTF3 (Nilsson et al. 2009) , and KITLD (Parrott & Skinner 1999) . Therefore, these factors likely affect follicle transition by acting through other parallel signaling pathways, rather than MAPK exclusively. C-erbB2 signaling has been shown to promote primordial follicle development in rats, and this increased follicle transition was blocked by treatment with the MAPK inhibitor PD98059 (Li-Ping et al. 2010) , suggesting an active role for MAPK signaling in this process. In addition, IL16 signaling through the CD4 receptor has been shown to activate MAP kinases in immune B-cells, as well as NFkB and P27 signaling pathways (Yang et al. 2013) . A cross-talk between several intracellular pathways is likely when regulating the primordial-to-primary follicle transition, including MAPK, NFkB, PI3K, and PTEN (Jin et al. 2005 , Serafica et al. 2005 , Liu et al. 2006 , Jagarlamudi et al. 2009 , Adhikari et al. 2013 , Morohaku et al. 2013 . Therefore, the signaling that occurs within the MAPK pathway may have effects that are distributed across other pathways, such as PI3K. It is possible that inhibiting JNK with SP600125 allows cross-talk to other pathways and therefore has little effect on follicle transition, while inhibiting MEK in the MAPK pathway with PD98059 does slow follicle transition when ovaries from 2-day-old rats are treated. In the current experiments, it has been demonstrated that a completely intact MAPK signaling pathway, including fully functional JNK, is not necessary for the primordial-to-primary follicle transition. Increasing MAPK pathway activity with BCI also did not result in increased follicle transition. Therefore, IL16 treatment appears to increase follicle transition through additional parallel signaling pathways, rather than MAPK alone. A previous study suggested that TGFB pathway signaling was another mechanism regulating the primordial-to-primary follicle transition (Nilsson et al. 2010) . In order to determine whether disruption of a specific branch of the TGFB signaling pathway affects primordial follicle transition, a third tyrphostin inhibitor was selected for use in organ culture experiments. The tyrphostin inhibitor LDN inhibits BMPRI within the TGFB signaling cascade (Cuny et al. 2008; Fig. 5) . BMPs induce many different cellular effects ranging from stem cell maintenance, migration, differentiation, and proliferation to apoptosis depending on context (Sieber et al. 2009 ). AMH also binds to BMPR1 (Cuny et al. 2008) , and has been shown in previous studies to inhibit primordial follicle assembly and transition (Durlinger et al. 1999 , Visser & Themmen 2005 , Nilsson et al. 2007 , 2011 ). In the current study, LDN was shown to have a significant effect on ovarian primordial-to-primary follicle transition. These previous observations suggest that LDN treatment would increase the percentage of developing follicles. This was verified by the results of this study. When combined with AMH, there was still a significant increase in the percentage of primary follicles as compared with the controls, likely indicating LDN is blocking the activity of AMH at the receptor. Together, these data indicate that signaling through the BMPR1 branch of the TGFB pathway regulates the primordialto-primary follicle transition (Fig. 11) . This is consistent with previous studies showing that the growth factors AMH and BMP4 affect primordial follicle transition (Nilsson & Skinner 2003 , Nilsson et al. 2007 , van Houten et al. 2010 , Buratini & Price 2011 and helps to validate the predictions of previous systems biology investigations (Nilsson et al. 2010 ) that suggested the TGFB signaling pathway helped to regulate this process.
Conclusions
In summary, specific signaling networks and candidate regulatory factors were tested for their roles in the regulation of early follicle development. Based on inhibitor experimentation in this study, the MAPK signaling pathway was shown to be important for the regulation of primordial follicle assembly. IL16 has now been shown to play an active role in the regulation of transition from primordial follicles with arrested oocytes into primary follicles with developing oocytes and proliferating granulosa cells. IL16 and its receptor CD4 were also specifically localized to the granulosa cells of developing follicles. Both Wnt2b and DLL4 treatment could have indirect roles with regard to primordial follicle transition within the ovary, but while mRNA expression of these cytokines was regulated within the ovary (Nilsson et al. 2010 ; Fig. 7 ), neither Wnt2b nor DLL4 treatment had a direct effect on primordial-to-primary follicle transition in cultured ovaries. The TGFB signaling pathway through BMPR1 was shown to be important for regulating primordial-to-primary follicle transition. Therefore IL16, the MAPK pathway, and the TGFB pathway were experimentally confirmed to be a part of the network of signaling molecules and pathways that regulate early ovarian follicle development (Fig. 11) .
The results of these studies support the utility of the previously proposed gene networks in the identification of candidate regulatory points to control follicle development (Nilsson et al. 2010 (Nilsson et al. , 2011 . A systems biology approach to study the developmental processes can be a tool that is complementary to the more reductionist experiments, such as performed in the current investigation. Some findings from this study supported the predictions from the systems biology investigations and some did not. This emphasizes the importance of using both experimental approaches.
Oocyte maturation and follicle development are complicated processes and the pathways and factors Cytokines and primordial follicle development regulating primordial follicle assembly and primordialto-primary follicle transition are still being determined. Understanding the regulators of early follicle development could lead to solutions for certain types of infertility in mammals, including humans. POI leading to early menopause (Dixit et al. 2010 ) is increasingly becoming a detriment to female reproductive success. Further investigation of the cytokine and hormonal signaling cascades involved in ovarian development will help to advance and improve treatments to combat ovarian disease.
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